BioRestorative Therapies (BRTX) Q4 2024 earnings summary

Executive summary

• Revenue increased 175% year-over-year to $401,000 for 2024, with net loss reduced by 14% and significant operational improvements.

• Ended 2024 with $10.7 million in cash, cash equivalents, and marketable securities, and no debt.

• Achieved major clinical milestones, including FDA Fast Track designation and IND clearance for BRTX-100 in lumbar and cervical disc disease, and positive Phase 2 data.

• Expanded regulatory clearances, including a provisional NYSDOH license for allogeneic tissue processing.

• Advanced BRTX-100 and ThermoStem programs, with positive early clinical and preclinical data.

Financial highlights

• 2024 revenue reached $401,000, up from $146,000 in 2023, a 175% increase.

• Net loss for 2024 was $9 million ($1.16 per share), a 14% improvement from 2023.

• Loss from operations improved by 24% to $11.6 million compared to 2023.

• Cash used in operating activities was $8.2 million.

• Ended 2024 with $10.7 million in cash, cash equivalents, and marketable securities, and no outstanding debt.

Outlook and guidance

• Focus remains on advancing BRTX-100 and ThermoStem clinical programs and managing resources efficiently.

• Ongoing discussions for potential licensing of ThermoStem metabolic IP and exploration of first-in-human clinical trial.

• Plans to expand BioCosmeceutical product offerings and pursue IND-enabling studies for new cell-based therapeutics.

• Cash burn in 2025 expected to be similar or slightly less than 2024, with further reductions anticipated in 2026.

• Anticipates more consistent commercial revenue from partnerships, with potential new announcements forthcoming.